Zhejiang Conba Pharmaceutical (600572.SH) announced its half-year report for 2024, with operating revenue of 3.448 billion yuan, a year-on-year decrease of 8.40%; net profit attributable to shareholders of listed companies was 0.382 billion yuan, a year-on-year decrease of 25.95%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 0.336 billion yuan, a year-on-year decrease of 19.02%; basic earnings per share were 0.150 yuan.

In the first half of 2024, the company firmly implemented the strategic focus on the development of traditional Chinese medicine health core business, actively responded to industry policies and market changes, and continued to promote the three major projects of big brands and varieties, technology-driven development, and talent-driven enterprise.

During the reporting period, the company achieved operating revenue of 3.448 billion yuan, a year-on-year decrease of 8.40%. This was mainly due to the significant increase in market demand for gastrointestinal and respiratory system drugs in the same period last year. In this reporting period, the market demand for related varieties returned to normal, leading to a decrease in sales compared to the same period last year. During the reporting period, the company achieved a net profit attributable to shareholders of listed companies of 0.382 billion yuan, a year-on-year decrease of 25.95%; and a net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 0.336 billion yuan, a year-on-year decrease of 19.02%. This was mainly due to the decrease in operating profit caused by the decrease in operating revenue during the reporting period and the increased R&D investment, which resulted in an increase in R&D expenses of approximately 40 million yuan compared to the same period last year.